12:00 AM
 | 
Oct 18, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 10/15 cls
Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) Piper Jaffray Edward Tenthoff Downgrade Neutral (from overweight) -56% $1.32
Tenthoff also lowered his target to $1.35 from $3.50 after FDA issued a complete response letter for an NDA for Adusuve Staccato loxapine (AZ-004) to treat agitation in patients with schizophrenia or bipolar disorder. According to Alexza, the agency is concerned with data from three Phase I pulmonary safety studies in which dose-related post-dose decreases in forced expiratory volume in one second (FEV1) were seen in healthy subjects and in subjects with chronic obstructive pulmonary disease (COPD) and asthma. AZ-004 is loxapine delivered by Alexza's Staccato system inhaler (see "Staccato Stumble," A13).
Alkermes Inc. (NASDAQ:ALKS) Jefferies David Windley Downgrade Hold (from buy) -7% $14.80
...

Read the full 875 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >